Top Tech Companies (2,070)
Don't see your company?
Create a company profile
OneSkin is a longevity company on a mission to transform the way we think about skin and aging. Founded by a team of four female PhDs, OneSkin’s products aim to extend skinspan, the period of time skin is healthy and functional. OneSkin’s proprietary peptide, OS-01, is the first ingredient designed to reduce skin's biological age by improving skin barrier, supporting DNA damage repair, and preventing the accumulation of aged cells.
Founded by Flagship Pioneering, Cellarity is the first company developing medicines through an understanding of cell behaviors. The company’s broad platform harnesses single-cell technologies and machine learning to digitize and quantify cellular behaviors, unravel the network dynamics that govern those behaviors, and generate medicines that can direct them. Cellarity is using its platform to design medicines targeting the full cellular and molecular complexity of disease, enabling a quantum leap in the success rate and speed of drug discovery.
As much as 99% of bacteria in the natural world can’t be seen with the human eye and are unknown. Uncovering the secrets of microbes & biodiversity should be the scientific quest for our era. BiOWiSH® provides industry-leading biotechnology solutions for the agriculture and environmental management industries. Our product range is proven to deliver consistent performance globally for agricultural applications, aquaculture production, and the water treatment industry. Led by former P&G scientists and senior executives based in Cincinnati, Ohio, the company has formed partnerships with leading research institutions around the world, to explore and develop a wide range of commercial applications for its proprietary technology. BiOWiSH Technologies was formed to commercialize composite biocatalysts and probiotics derived from a unique blend of naturally occurring microorganisms, enzymes, and co-factors. These materials enhance the rate and efficiency of biochemical systems over a wide range of environmental conditions.
Better Therapeutics ("Better") is developing first-in-class prescription digital therapeutics to deliver behavioral therapy to patients. Led by an experienced team of biotechnology executives with funding from top-tier industry investors, Better went public through a merger with SPAC Mountain Crest Acquisition Corp. (NASDAQ: MCAD) during the fall of 2021. Better was founded upon the realization that nearly half a trillion dollars are spent each year treating the symptoms or effects of cardiometabolic diseases while little is being done to address the behaviors that cause them. Better has created prescription software that it believes has the opportunity to fundamentally change the treatment of a broad range of cardiometabolic diseases beginning with type 2 diabetes. The team is focused on creating significant patient impact through the launch of their first product in 2023. Better is developing a portfolio of regulated software products that treat the root causes of disease, improving the health and quality of life of patients while giving providers and payers access to cost-effective digital behavior therapies. Better Therapeutics operates as a fully distributed company combining remote work with periodic team and all-hands in-person meetings. We are headquartered in San Francisco, CA and have employees located in 15 states across the country.
UVision360 has created the Luminelle DTx Hysteroscopy System to support the market shift to office based procedures.
ZAGENO is on a mission to accelerate scientific innovation by streamlining biotech purchasing processes with its award-winning, first-of-its-kind e-commerce platform. With over 25 million product SKUs available from more than 5,000 unique product brands, ZAGENO makes online shopping for any research material convenient, efficient and reliable. The ZAGENO experience includes its Scientific Score, a best-in-class product rating system that offers unbiased, peer-reviewed ratings to support accurate purchasing decisions. Available on desktop, tablet, and mobile devices, ZAGENO makes biotech purchases easier than ever and is an ideal sales channel for suppliers and partners. Founded in 2015, the company is headquartered in the United States and has additional offices in Germany, and Poland. For more information, visit www.zageno.com.
Dr. Raj Krishnan founded Biological Dynamics in 2010 with the goal to revolutionize diagnosis and treatment of high burden diseases. Under Raj's vision and guidance, Biological Dynamics has transformed from concept to early-stage startup and is now one of the most innovative diagnostic companies in Southern California. His passion and conviction have led Biological Dynamics through multiple rounds of funding, securing over $75 million in total. Raj has been recognized in the Top 30 under 30 scientists by Forbes magazine.
Spinal Elements, Inc. is an innovative spine technology company that delivers new standards in spine surgery. Located in Carlsbad, California, Spinal Elements is known for its ability to design and bring to market products and procedures that introduce and set new industry standards. We have built a reputation as consistently Delivering a New Standard in all dimensions of our company.
nference is making the world's biomedical knowledge computable to solve urgent healthcare problems. The company was co-founded by Venky Soundararajan, Ph.D. and Murali Aravamudan.
TAMM Net professionals provide biomedical companies with expertise in: •Obtaining reimbursement, •Researching government funding resources, •Providing solutions to regulatory issues and applications, and •Supplying distribution to closed systems. Everyone on the TAMM Net team has over 20 years of experience in their fields with documented success.
CIS Biotech is a research and development company bringing disease-associated biomarkers and in vitro diagnostic tools to the marketplace.
Arkuda Therapeutics is a biotechnology company leveraging new insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease.
We are a pioneering healthcare company that aims to transform health through the power of genomics. The company was formed in 2014 by four world-leading statistical and human geneticists at the University of Oxford, including Professor Sir Peter Donnelly and Professor Gil McVean. We use large-scale genetic information to realise preventative medicine and improve drug discovery. We're a world-leader in genomic prevention: a paradigm-changing approach to sustainable healthcare which for the first time allows reliable, personalized estimates of risk for all the common diseases and cancers, well ahead of disease manifestation, allowing accurate and early interventions and tailored screening. Our proprietary algorithms and databases offer something no competitor can: the ability to accurately link minute variation across the entire genome to changes in thousands of biological measurements and disease outcomes, to generate population-level insights for healthcare systems, individual-level insights for clinicians about the risk of common diseases, and new understanding of disease processes. In August 2018, we announced a multi-year collaboration with Vertex to use human genetics and data science to advance discovery of precision medicines. We also has several pilot programmes in development within UK and US healthcare systems. Our team is a multi-disciplinary group focused on finding powerful and creative solutions for bringing subject-leading science to as wide an audience as possible, and, in doing so, offer the chance of transforming lives around the world. The workforce is highly qualified and consists of over 90 people, including genomic scientists, computational biologists, statisticians, software engineers, product developers, data scientists and commercial strategists. We are headquartered in Oxford, with offices in Cambridge (UK) and Boston (US).
ATUM, formerly DNA2.0, offers an integrated pipeline of tools including gene design, optimization and synthesis, expression vectors, and platforms for protein and strain engineering and production. ATUM exploits the dependence of biological activity on well-designed sequences. ATUM’s tools and solutions are fueling the transformation of biology from a discovery science to an engineering discipline. By collaborating with our clients, ATUM accelerates breakthroughs and moves research further faster.
Oragenics develops oral probiotic products and antibiotics for humans and companion pets.
Elemental Machines is helping scientists improve experimental reproducibility and accelerate scientific discovery. With a new suite of connected products that harness the power of cloud-based software, machine learning and distributed sensors, Elemental Machines is giving scientists and researchers an easy, powerful and cost-effective solution fo
ArriVent is dedicated to accelerating the global development of innovative biopharmaceutical products. With a deep and global network, ArriVent seeks to access unique and best-in-class drug candidates at various development stages, including those coming from China and other emerging biotech hubs. Through strategic collaborations with innovative biopharma companies, ArriVent aims to globalize medicines for patients with unmet medical need in a broad range of diseases, with an initial focus in oncology.
AmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the development and delivery of pharmaceuticals and healthcare products. As a leading global healthcare company, with a foundation in pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency and reliability for human and animal health. Our 41,000 global team members power our purpose: We are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual revenue.
Boost Biomes is using the powerful social networks among microbes to provide novel, sustainable solutions to feed and heal people everywhere. Our technology differentiator is the development of a causal understanding of microbial interactions powerful enough to allow the rational construction of designer functional consortia. Our first products seek to reduce the enormous waste in agricultural products due to crop loss to fungal pests in the field and post-harvest. There is significant need for new biological, organic, safe biopesticides for crops; current chemical products have many challenges, including regulatory burden for growers and safety concerns of consumers.
Based on an R&D program started in 2005, Orano Med has developed new processes for producing high-purity lead-212 (Pb-212), a rare radioactive isotope. Lead-212 is currently at the heart of promising projects in nuclear medicine to develop new treatments against cancer. The innovative approach, known as targeted alpha therapy (TAT), recognizes and destroys cancer cells while limiting the impact on nearby healthy cells. Macrocyclics, Inc., an Orano Med company, is the global leader in high performance chelating agent technology, offering a broad range of services and products. For more information please visit www.macrocyclics.com.
